Therapy Food and Drug Administration (“FDA”) Breakthrough Device Designations span the broader population of patients with uncontrolled hypertension despite medication at increased cardiovascular risk ...

Orchestra BioMed (Nasdaq:OBIO) announced today that it received a second FDA breakthrough device designation for its AVIM ...

Bio-Med Devices Inc. has been shaping the future of respiratory care for over 50 years, but its story is more than a timeline – it’s a legacy built on family, risk and deep-rooted purpose. The company ...

Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S. patients ...

Orchestra BioMed’s hypertension treatment is the latest medical device to earn the FDA’s breakthrough designation. The device is an atrio-ventricular interval modulation therapy, meaning it uses a ...

Orchestra BioMed Holdings' AVIM product received FDA breakthrough device designation, accelerating approval and offering speculative optimism for investors. The firm is pre-revenue with significant ...

Orchestra BioMed Holdings, Inc. announced significant regulatory advancements and financial results for the first quarter of 2025, including the recipient of FDA Breakthrough Device Designation for ...

As quantum computers advance, they are expected to be able to break tried-and-true security schemes that currently keep most sensitive data secure from attackers. Scientists and policymakers are ...

Breakthrough Device Designation (“BDD”) applies to an estimated U.S. population of over 7.7 million patients with uncontrolled hypertension and increased cardiovascular risk BDD also encompasses ...